A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Electromed, Inc. (“we,” “our,” “us,” “Electromed” or the “Company”) develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest® Airway Clearance System (“SmartVest System”) to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation (“HFCWO”) treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations. We primarily employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients, and deliver the SmartVest System to patients, training them on proper use in their homes.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 69M | 64M | 55M | 48M | 42M | 36M |
| Net Income | 9.0M | 7.5M | 5.2M | 3.2M | 2.3M | 2.4M |
| EPS | $1.03 | $0.85 | $0.58 | $0.36 | $0.26 | $0.27 |
| Free Cash Flow | 8.3M | 11M | 8.8M | -333K | -2.1M | 2.8M |
| ROIC | 48.2% | 56.6% | 38.9% | 13.5% | 12.8% | 26.8% |
| Gross Margin | 78.2% | 78.1% | 76.3% | 76.0% | 75.5% | 76.4% |
| Debt/Equity | 0.00 | 0.25 | 0.17 | 0.00 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 11M | 9.7M | 6.6M | 4.0M | 3.0M | 3.1M |
| Operating Margin | 16.7% | 15.1% | 12.0% | 8.3% | 7.1% | 8.8% |
| ROE | 19.8% | 17.2% | 11.6% | 8.4% | 6.7% | 7.3% |
| Shares Outstanding | 8M | 9M | 9M | 9M | 9M | 9M |
Electromed, Inc. passes 7 of 9 quality checks, indicating strong fundamentals.
Electromed, Inc. trades at 24.5x trailing earnings, compared to its 15-year median P/E of 25.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 25.3x vs a median of 30.2x. The company's 5-year average ROIC is 29.7% with a gross margin of 76.4%. Total shareholder yield (buybacks) is 4.4%. At current prices, the estimated annualized return to fair value is +24.9%.
Electromed, Inc. (ELMD) has a current P/E ratio of 24.5, compared to its historical median P/E of 25.9. The stock is currently considered Fair based on its historical valuation range.
Electromed, Inc. (ELMD) has a 5-year average return on invested capital (ROIC) of 29.7%. This indicates strong capital allocation and a potential competitive advantage.
Electromed, Inc. (ELMD) has a market capitalization of $209M. It is classified as a small-cap stock.
Electromed, Inc. (ELMD) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.42%.
Based on historical P/E analysis, Electromed, Inc. (ELMD) appears fair. The current P/E of 24.5 is 5% below its historical median of 25.9. The estimated fair value CAGR (P/E method) is 15.1%.
Electromed, Inc. (ELMD) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Electromed, Inc. (ELMD) reported annual revenue of $64 million in its most recent fiscal year, based on SEC EDGAR filings.
Electromed, Inc. (ELMD) has a net profit margin of 11.8%. This is a healthy margin.
Electromed, Inc. (ELMD) generated $11 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Electromed, Inc. (ELMD) has a debt-to-equity ratio of 0.25. This indicates a conservatively financed balance sheet.
Electromed, Inc. (ELMD) reported earnings per share (EPS) of $0.85 in its most recent fiscal year.
Electromed, Inc. (ELMD) has a return on equity (ROE) of 17.2%. This indicates the company generates strong returns for shareholders.
Electromed, Inc. (ELMD) has a 5-year average gross margin of 76.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for Electromed, Inc. (ELMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Electromed, Inc. (ELMD) has a book value per share of $4.87, based on its most recent annual SEC filing.